Therapeutic | Burosumab |
Target | FGF23 |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSS |
Light Chain | AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | Kyowa Hakko Kirin, Ultragenyx Pharmaceutical |
Conditions Approved | X-linked dominant hypophosphataemic rickets |
Conditions Active | Osteomalacia, Nevus |
Conditions Discontinued | na |
Notes |